INTRODUÇÃO: Indivíduos infectados pelo HIV apresentam maior risco de quadros graves de infecção por influenza sazonal e, portanto, devem receber doses anuais da vacina contra gripe. No entanto, a capacidade dos indivíduos responderem às vacinas com títulos apropriados de anticorpos depende de variáveis como tipo de antígeno vacinal, idade e grau de comprometimento imunológico no momento da imunização. OBJETIVOS: 1) Avaliar a imunogenicidade da vacina contra influenza sazonal em 37 pacientes infectados pelo HIV, em comparação com 29 indivíduos não infectados pelo HIV 2) Realizar a vigilância dos episódios de infecções respiratórias durante o período de acompanhamento após a vacinação. MÉTODOS: Ambos os grupos receberam a vacina contra o vírus da influenza sazonal recomendada para o hemisfério sul em 2008. A resposta de anticorpos contra os antígenos H1N1, H3N2 e B foi medida em amostras de sangue extraídas 1-2h antes da vacinação (T0), após 1 mês (T1) e após 6 meses (T6; apenas no Grupo HIV). A vigilância dos sintomas respiratórios foi realizada através de telefonemas semanais, durante 6 meses após a vacinação. Em indivíduos sintomáticos para infecções respiratórios foram coletadas amostras de lavado nasofaríngeo para pesquisa de vírus respiratórios por Imunofluorescência e PCR: influenza A e B, parainfluenza 1, 2 e 3, adenovírus, metapneumovírus, vírus sincicial respiratório, rinovírus e coronavírus. RESULTADOS: A idade mediana da população de estudo foi de 12 (10-18) anos. No momento T1, ambos os grupos mostraram aumento significativo nos TMGs para todos os antígenos. Contudo, o grupo controle apresentou valores mais elevados para os antígenos A/H1N1 e A/H3N2 (p = 0,002 e 0,001, respectivamente). Houve maior aumento na porcentagem de indivíduos não infectados pelo HIV com títulos protetores A/H1N1 (96,6%) em comparação aos infectados pelo HIV (67,6%). No T1 (p=0,004). A porcentagem de indivíduos do grupo controle com aumento de quatro vezes ou mais nos títulos de anticorpos para A/H1N1 e A/H3N2 foram mais elevadas que no grupo HIV (p = 0,03 e 0,01, respectivamente). Agentes virais foram detectados em 39/60 (65%) dos episódios de infecção respiratória no grupo HIV e em 17/32 (53,1%) no grupo controle. Os vírus diagnosticados no grupo HIV e grupo controle foram respectivamente: adenovirus (8,6%), metapneumovirus (1,2%), rinovirus (16,8%), coronavirus (14,0 %) e influenza B (0,1%).CONCLUSÕES: A vacina sazonal contra os vírus da influenza foram imunogenicas em ambos os grupos. Ocorreram diferença nas taxas de soroproteção entre os grupos somente para o antígeno H1, que foi mais elevadas no grupo controle. O grupo controle também mostrou valores mais altos nos TMGs para os antígenos H1 e H3 depois da imunização. Os rinovirus (27,7%) e coronavirus (22,5%) foram os agentes mais prevalentes identificados no grupo infectado pelo HIV. No grupo controle, os vírus mais freqüentes foram os rinovirus (24,2%) e adenovirus (21,2%) / INTRODUCTION: Individuals infected with HIV are at higher risk for severe cases of seasonal influenza infection and therefore should receive annual doses of influenza vaccine. However, the ability to respond to vaccines respond appropriate antibodies titres depends on variables such as vaccine antigen, age and degree of immune impairment at immunization. OBJECTIVES: 1)To evaluate the immunogenicity of a seasonal influenza vaccine in 37 HIV-infected patients (HIV Group), compared to 29 uninfected individuals (Control Group) 2) To carry out a clinical and virological surveillance of influenza in this population during a follow-up period of six months. METHODS: Both groups received the vaccine against seasonal influenza virus recommended for the southern hemisphere in 2008. The antibody response against the antigens H1N1, H3N2 and B were measured in blood samples drawn at vaccination (T0), after 30 days (T1) and after 6 months (T6; only for HIV Group). Antibody titres >1:40 were considered protective against influenza infection A surveillance of respiratory symptoms was performed weekly by telephone calls for a post-vaccination follow-up period of 6 months. Samples were collected (nasal wash) if respiratory symptoms. DFA and real time PCR was used to diagnose influenza A virus (FLU A) and B (FLU B), respiratory syncytial virus (RSV), parainfluenza virus types 1, 2 and 3 ( Paraflu 1, 2 or 3), adenovirus, coronavirus, rhinovirus, metapneumovirus and bocavirus. RESULTS: The median age of the study population was 12 (10-18) years. At T0, there were no significant differences in the antibody geometric mean titres (GMTs) against all vaccine antigens between groups. One month after vaccination (T1), both groups showed significant increases in the antibody GMTs for all antigens. However, healthy controls showed higher values for antigens A/H1N1 and A/H3N2 (p = 0.002 and 0.001, respectively). There was a higher increase in the percentage of HIVuninfected subjects with protective A/H1N1 antibodies (96.6%) comparing to HIVinfected vaccinees (67.6%) at T1 (p = 0.004). The percentage in subjects control group with a fourfold or greater increase of A/H1N1 and A/H3N2 antibody titres was higher than that found in HIV group (p = 0.03 and p = 0.01, respectively. Viral agents were identified in 39/60 (65%) episodes of respiratory infections in HIV-infected group and in 17/32 episodes (53.1%) from the control group (P=0.273). The virus diagnosed in HIV group and control group were, respectively: Adenovirus (8;6), Metapneumovirus(1;2) Rinovirus(16;8), Coronavirus(14 ;0); Influenza B(0;1). CONCLUSIONS: The seasonal influenza vaccine was immunogenic in both groups. There were differences in seroprotection rates between groups only for AgH1, which was higher in the control group. The control group also showed a greater increase in GMTs for H1 and H3 antigens after immunization. Viral agents were identified in respiratory symptoms during the follow-up: Rhinoviruses (27.7%) and coronavirus (22.5%) were the most prevalent agents identified in HIV-infected individuals. In the control group, the viruses most frequently found were rhinoviruses (24.2%) and adenovirus (21.2%)

Nontypeable Haemophilus influenzas (NTHi) is recognised as a significant human pathogen causing mild to severe respiratory tract infections. At present, no vaccine is available for prevention of infection caused by this pathogen. Several outer membrane proteins (OMPs) of NTHi and its lipooligosaccharide have been investigated as possible vaccine antigens against NTHi infections. Previous investigations in our laboratory have shown that OMP26 from an NTHi 289 strain was able to significantly enhance pulmonary clearance of NTHi in a rat model in which animals were immunised via intestinal Peyer's patches and then boosted intratracheally (Kyd and Cripps, 1998; El- Adhami et al., 1999). In recent studies, the OMP26, when used as a parenteral immunogen, was also highly effective at inducing immune responses that led to significantly enhanced clearance of the chinchilla nasopharynx (Kyd et al., 2003). These studies indicate significant potential of the OMP26 as a candidate vaccine antigen and warrant further investigations for development of a vaccine against NTHi. This thesis focussed on the immunological and structural characterisation of the NTHi vaccine candidate, OMP26. Peptides of OMP26 were used as tools to localise the immunologically important regions of the OMP26. Two different E. coli expression systems, the GST gene fusion and the 6xHis tagged systems, were employed to construct the OMP26 peptides. It was found in this study that, despite efforts to optimise the system, the GST-fusion protein system failed to produce consistent results for the purification and storage of the OMP26 peptides. In contrast, the 6xHis tagged system exhibited more reliable outcomes in the production of the recombinant OMP26 peptides and the stability of the stored purified peptides. As such, the purified OMP26 peptides from the 6xHis tagged system were chosen to map major regions of immunological significance for the OMP26 protein. The regions of the OMP26 which are involved in the induction of the acquired immune responses have been identified in the present study. Based on the antigen specific lymphocyte proliferation assay, the dominant T cell epitopes for OMP26 were located between amino acid residues 95 and 197 (T3+T4 region). These identified T cell epitopes exhibited the capability of efficient T cell activation, suggesting that the epitopes within the T3+T4 region potentially had the highest affinity for binding to the MHC molecules than did any other OMP26 region. Using two different assay systems, ELISA and BIA, the predominant B cell epitopes of OMP26 were located between amino acid residues 45 and 145 (T2+T3 region). This region was also found to be immunodominant across all animal species tested, and with all immunisation regimens used. Flow cytometry analysis also revealed that these particular epitopes were expressed on the surface of NTHi cells. By integration of the data obtained from these current experimental studies and the computational analysis of the OMP26 sequence, two hypothetical models of the OMP26 were also proposed in this study. The significant outcomes obtained in this thesis provide a better understanding of the specificity of the host immune responses to the OMP26 protein These findings provide great benefit not only for the development of a future NTHi vaccine but for the development of the peptide-based immunodiagnostic reagents as well. These diagnostic reagents will be valuable, in particular, for the evaluation of efficacy of an NTHi vaccine in humans that may include OMP26 or specific conformational structures. Future studies are still required to further define the minimum epitope length required for the B and T cell responses identified in this study. The significance of these responses in immune protection against NTHi infection also requires further investigations. Human immune responses also need to be determined, but this can only be achieved following clinical trial studies.

Emergency departments (EDs) are the only source of medical care for many adults and have been found to be feasible venues for vaccinating high-risk patients against seasonal influenza. Since the CDC guidelines expanded in 2008 to include any adults wishing to protect themselves and those around them from the flu, the vaccination of low-risk patients in the ED has not been evaluated. This study sought to assess the acceptability among adult patients of all ages for vaccinating against seasonal influenza in the Urgent Care area of an urban ED, which treats primarily healthy adults. A convenience sample of adult patients in the Urgent Care area was surveyed in November 2009. Subjects were asked about their vaccination history, as well as their perceived need and potential acceptance of a vaccine in the ED. Demographic data obtained included age, race, education, insurance status, medical history, access to primary care and contact with high-risk individuals. 381 patients were approached, of whom 352 completed the survey (92.4%; 56% male, 44% female; mean age 36 years, Standard Deviation 12.4), and 349 were vaccine-eligible. 250 (72%) denied any significant medical history. While 169 patients (48.4%) had an influenza vaccination history, only 69 (20%) were vaccinated in 2009. Of the 280 not vaccinated this year, 179 (64%) would have accepted the vaccine in the ED. Factors associated with increased odds of vaccine acceptance in the ED included: age younger than 50 years (Odds Ratio [OR] 3.28, 95% Confidence Interval [CI] = 1.74 to 6.21, p<0.01), Latino/Hispanic ethnicity (OR 2.89, 95% CI = 1.52 to 5.51, p<0.01), and close contact with high-risk individuals (OR 2.28, 95% CI = 1.33 to 3.92, p<0.01). These results suggest that the majority of relatively healthy adult patients would accept the seasonal influenza vaccine in the ED. Although a shortage of vaccines and increased vigilance during a concurrent H1N1 outbreak may have influenced overall acceptability, we conclude that influenza vaccinations during the ED patient encounter would generally be acceptable to patients as a means to improve their overall health, and indirectly the health of their high-risk close contacts.

published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

published_or_final_version / Public Health / Master / Master of Public Health

published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

published_or_final_version / Community Medicine / Doctoral / Doctor of Philosophy

É de grande relevância o conhecimento dos eventos adversos ocorridos após aplicação da vacina contra Influenza em idosos, visando sua identificação e possíveis intervenções preventivas. Considera-se que os idosos são assistidos por equipe de enfermagem que atua em hospitais, Unidades Básicas de Saúde, em domicílios ou em Instituições de Longa Permanência. Eventos adversos ocorridos após aplicação da vacina contra Influenza em idosos institucionalizados foram os motivadores para o desenvolvimento do presente estudo. Objetivos: Identificar e analisar a ocorrência de eventos adversos após vacinação contra Influenza em idosos de Minas Gerais, caracterizar os dados sócio demográficos e suas associações; confeccionar material educativo direcionado aos enfermeiros que atuam no cuidado aos idosos. Método: Pesquisa descritiva-analítica, retrospectiva e quantitativa; a amostra foi composta por 98 idosos de ambos os sexos, que corresponderam a 12,9% da população inicial, identificados por meio das Fichas de Notificação de Eventos Adversos Pós Vacinação, disponibilizados pelo Sistema de Informação de Eventos Adversos Pós Vacinação de Minas Gerias - BR, entre 2014 e 2016. Os dados foram duplamente digitados e transportados para o programa Ri386 versão 3.4.3 3 IBM SPSS Statics versão 25. Realizou-se estatísticas descritivas, frequência e percentual para as variáveis qualitativas e medidas de tendência central (média e mediana) e dispersão (desvio padrão) para as variáveis numéricas. Para verificar a associação entre os tipos de eventos (não grave, grave e erro de imunização) e as manifestações sistêmicas com as variáveis de caracterização dos idosos e das vacinas, utilizou-se o teste Exato de Fisher e Qui-quadrado; o nível de significância utilizado foi p < 0,05. Após a análise e discussão dos dados procedeu-se a confecção do material educativo. Resultados: Os eventos adversos não graves representaram 84,7% das notificações obtidas, eventos adversos graves, 5,1% e erros de imunização, 10,2%. Os testes revelaram significância estatística para eventos adversos não graves e a variável sexo (p=0,042) mais entre as mulheres que apresentaram manifestações locais, ou seja, 70,3% e entre os homens que apresentaram manifestações clínicas sistêmicas (p=0,021) - 45,8%, as quais foram caracterizadas por sintomas neurológicos. Erro de imunização se caracterizou por aplicações duplas do mesmo imunobiológico por falta de informação ou esquecimento do cartão de vacinas. Conclusão: O conhecimento do enfermeiro sobre a temática em estudo é de fundamental importância para um atendimento adequado livre de danos ao idoso para que não incorra em eventos adversos evitáveis. O material educativo se apresenta como ferramenta para orientar o enfermeiro que assiste o idoso seja em uma Instituição de Longa Permanência, seja numa Unidade de Saúde da Família, Unidades Básicas de Saúde, hospitais ou em domicílio. Espera-se que este estudo desperte interesse para futuras pesquisas relacionadas à compreensão do surgimento dos eventos adversos pós vacinação contra Influenza em idosos, visando a prevenção de tais eventos e suas consequências, assim como estimule a adesão às campanhas vacinais / It is highly important to be aware of the adverse events that occur after the elderly are vaccinated against influenza in order to identify them, therefore making preventive measures possible. It is considerable that the elderly are cared for by nursing teams who work in hospitals, Basic Healthcare Units, residences or in Long Stay Institutions. The adverse events in elderly after they were vaccinated against influenza were the motivators so this study could be developed. Objectives: Identify and analyze the occurrence of the adverse events after the elderly from Minas Gerais are vaccinated against influenza, characterize the socio demographic data and their associations, prepare socio educative material addressed to nurses who work in caring for the elderly. Method: Quantitative, retrospective and descriptiveanalytical study. The sample was composed for 98 seniors both sexes, men and women, covering a rate of 12,9% of the initial population, identified from Notification Sheets of Post-Vaccination Adverse Events, available in the Information of Post-Vaccination Adverse Events System from Minas Gerais - Br, between 2016 and 2016. The data were doubleentered and carried foward for the Program Ri386 version 3.4.3 3 IBM SPSS Statics version 25. Percentage, frequency and descriptive statistics were performed for qualitative variables and central tendency measures (mean and median), and dispersion (standard deviation) for numerical variables. In order to make the association among events possible (severe, nonsevere and immunization error) and the systemic manifestations with the elderly and vaccines variable of characterization, the Fisher\'s Exact and Qui-square tests were used and the significance level that was used was p < 0,05. After the analysis and the discussion of the data, the educative material was prepared. Results: The non-severe adverse events accounted for 84,7% of the obtained notifications, the severe adverse events, 5,1% and the immunization, 10,2%. The tests revealed statistical significance for the non-severe adverse events and the sex variation (p=0,042) better among women who presented local manifestations, that is to say 70,3% and, among men who presented systemic clinical manifestations (p=0,21) - 45,8%, which were characterized by neurological symptoms. The immunization error was characterized by double applications of the same immunobiological, either because of lack of information or vaccination card oversight. Conclusion: The nurse\'s expertise on the thematic being studied is really important for an appropriate caring free from damage to the elderly just so preventable adverse events can be avoided. The educative material is presented like a tool to guide the nurse who cares for the elderly in a Long-Stay Institution, in a Family Health-Care Unit, in Basic Health-Care Units, in hospitals or in residences. It is expected that this study motivates interest for future studies regarding the understanding of the development of different post-vaccination adverse events against influenza in elderly people, aiming the prevention of such events and their consequences. It is also expected that it motivates the accession to vaccination campaigns

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 4 uppsatser.

INTRODUÇÃO: Influenza é uma doença potencialmente grave após o transplante de células tronco hematopoiéticas (TCTH). A vacinação é a principal estratégia profilática, mas a resposta imune é menor do que em indivíduos saudáveis. Em geral os pacientes não respondem a vacinação nos primeiros seis meses após transplante, o que torna o período de maior vulnerabilidade. OBJETIVOS: Neste estudo avaliaram-se diferentes esquemas de vacinação contra influenza em TCTH alogênico relacionado, com imunização do doador e/ou do receptor no pré transplante. Determinou-se a resposta a vacina comparando-se as taxas de soroconversão entre os grupos de intervenção. Foram avaliados também os níveis de anticorpos considerados soroprotetores alcançados. MÉTODOS: Realizou-se ensaio clinico randomizado não cego, em população de candidatos ao TCTH e seus doadores do Hospital das Clínicas da Faculdade de Medicina da Universidade Federal de Minas Gerais/BH-MG e Hospital Amaral Carvalho/Jaú-SP. Quatro grupos de pares receptor-doador receberam diferentes esquemas de imunização de influenza no pré transplante: 1- sem vacinação, 2 - vacinação do doador; 3 - vacinação do receptor e 4 - vacinação de doador e receptor. Todos os pacientes receberam vacina a partir do 6º mês após transplante. Acompanhamento sorológico do par foi realizado no pré e no dia do transplante, e nos dias 30, 60, 100, 180 e após vacina apenas para os receptores. Títulos dos anticorpos sorotipo - específicos foram determinados pela reação de inibição de hemaglutinação. Níveis 1:40 foram considerados protetores e < 1:10 negativos. Soroconversão foi definida como aumento de quatro vezes ou mais dos títulos ou aumento de <1:10 para 1:40. RESULTADOS: De 08/2007 a 02/2010 131 pares receptor-doador foram incluídos e randomizados: 38 no grupo 1, 44 no grupo 2, 40 no grupo 3 e 9 no grupo 4. Não houve diferença estatística entre os grupos com relação às características clínicas. As taxas de soroproteção basal dos receptores foram de 18%, 32,8% e 63,3% para influenza A/H1N1, A/H3N2 e B, respectivamente. A condição sorológica pré transplante dos doadores foi semelhante. As taxas de soroconversão dos doadores foram de 30,1%, 41,5% e 30,9%, respectivamente para os A/H1N1, A/H3N2 e B. Nos receptores soroconversão até o dia 30 após transplante ocorreu em 16,3% dos pacientes para o A/H1N, 14,7% para A/H3N2 e 28,7%. As médias geométricas dos títulos de anticorpos neutralizantes foram calculadas para todos os subtipos virais ao longo do tempo. Para o A/H1N1 não houve diferença dos títulos até o D180 para nenhum dos grupos. Para o A/H3N2 houve diferença nos títulos no momento do transplante (p=0,019), com maiores títulos nos grupos 2 e 3 em relação ao grupo 1 e no dia 30 (p=0,018) com menores títulos para o grupo 4 que os demais. Para o subtipo B, as diferenças entre os grupos ocorreram no dia do transplante (p=0,020) e nos dias 30 (p= 0,018) e 60 (p=0,026) com menores títulos do grupo 4 em relação aos demais. As taxas de soroconversão após a vacina do dia 180 foram de 19,7% para o A/H1N1, 18% para o A/H3N2 e 8,2% para o B. Não houve diferença estatisticamente significante entre os grupos. CONCLUSÃO: A imunogenicidade da vacina de influenza em receptores de TCTH foi baixa. A estratégia de vacinação do doador e do receptor no pré transplante aumentou a média geométrica dos títulos protetores apenas para o subtipo A/H3N2 até o 30º pós transplante, em relação ao grupo sem vacinação / INTRODUCTION: Influenza is a potentially severe illness after hematopoietic stem cell transplantation (HSCT). Vaccination is the main prophylactic strategy, but the immune response is limited in the compromised host. Existing data support the recommendation of influenza vaccination after the 6th month of HSCT. OBJECTIVES: The study evaluated different schedules of influenza vaccination in HSCT. Recipient and/or their donors were randomized to receive influenza vaccine before transplant. The primary outcome was the comparison of serotype response between groups at baseline, 30 days and 6 months after transplantation. METHODS: A randomized, non-blind trial was conducted in patients undergoing HSCT and respective donors at Hospital das Clínicas, Universidade Federal de Minas Gerais /BH-MG and at Hospital Amaral Carvalho/Jaú-SP. Four groups of donor and recipient pairs received different influenza immunization at least 7 days before HSCT: group 1 no vaccination, group 2 donor received a single dose of influenza vaccine; group 3 recipients received a single dose of influenza vaccine and group 4 recipients and donor received influenza vaccine. Following transplantation, all study patients were immunized with influenza vaccine at 6 months. Donor serum samples were collected at baseline (pre transplantation) and in the day of transplantation. Recipients serum samples were taken at baseline, 30, 60, 100, 180 days after transplantation, and at least 2 weeks after 6-month vaccination. The hemagglutination inhibition assay (HIA) was performed to evaluate immune response. HI antibodies titers 1:40 were considered protective. Titers < 1:10 were considered negative. Antibody response (seroresponse) was defined as the appearance or 4-fold rise in HI antibody titers after vaccination. RESULTS: From August 2007 to February 2010 131 donor and recipient pairs were included in the study: 38 pairs in group 1, 44 in the group 2 , 40 in 3 group and 9 in group 4.There were no statistically difference between the 4 groups regarding to the clinical characteristics. At baseline 18% of recipients had protective antibody levels to A/H1N1, 32.8% to A/H3N2 and 63.3% to B. Donor serological condition was similar to recipients. Seroresponse occurred in 30,1% of donors to A/H1N1, 41,5% to A/H3N2 and 30,9% to B. Seroresponse until day 30 after transplant were detected in only 16,3% of the patients for the A/H1N, 14.7% for A/H3N2 and 28.7% for B. Comparisons of geometric mean antibody concentrations was performed at baseline and day of transplantation, and also at 30, 60, 100, 180 days after HSCT e after 6 months influenza vaccine. For the A/H1N1 there was no statistically difference between groups until 180 days after HSCT. For the A/H3N2 a significant increase in geometric mean titers in the day of transplantation (p=0,019) was observed in groups 2 and 3 in relation to group 1 and lower geometric mean titers (p=0,018) at day 30 for patients in group 4. For subtype B, the differences between groups occurred in the day of the transplantation (p=0,020) and at 30 (p= 0,018) and 60 (p=0,026) day. The geometric mean titers were lower in group 4 in relation to the others. Seroresponse after 6-month vaccination occurred in 19,7% to A/H1N1, 18% to A/H3N2 and 8.2% to B. There was no significant difference between the groups. CONCLUSION: Immunogenicity to influenza vaccine was poor in HSCT recipients. Donor or recipient vaccination strategy prior to transplantation increased the geometric mean titers only for subtype A/H3N2 at day 30 after transplant. No impact was observed in seroresponse rates after 6-month vaccination